Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
The Journal of Urology
|
July 24, 2007
Taxane refractory prostate cancer
Paul Mathew, Robert Dipaola
Clinical Genitourinary Cancer
|
March 6, 2012
Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group
Glenn Liu, Yu-Hui Chen, Robert Dipaola, et al.
Cancer
|
June 19, 2009
Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group
Robert Dreicer, Hailun Li, Mark Stein, et al.
Plos One
|
December 3, 2015
Combination of α-Tomatine and Curcumin Inhibits Growth and Induces Apoptosis in Human Prostate Cancer Cells
Huarong Huang, Xuan Chen, Dongli Li, et al.
American Journal of Infection Control
|
August 29, 2021
Prevalence of SARS-CoV-2 IgG antibodies in health care workers at a tertiary care academic medical center - An assessment of occupational infection risk
Derek Forster, Nan Lin, Justin Levens, et al.
Urologic Oncology
|
July 26, 2011
Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer
Glenn Liu, Yu-Hui Chen, Jill Kolesar, et al.
Investigational New Drugs
|
November 5, 2010
Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium
Ajjai Alva, Susan Slovin, Stephanie Daignault, et al.
Investigational New Drugs
|
March 23, 2011
A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors
Kyle Holen, Robert DiPaola, Glenn Liu, et al.
Clinical Genitourinary Cancer
|
May 30, 2006
Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design
Kathleen W Beekman, A Dimitrios Colevas, Kathleen Cooney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2018
Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer
Anna C Ferrari, Joshi J Alumkal, Mark N Stein, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
The Journal of Urology
|
July 24, 2007
Taxane refractory prostate cancer
Paul Mathew, Robert Dipaola
Clinical Genitourinary Cancer
|
March 6, 2012
Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group
Glenn Liu, Yu-Hui Chen, Robert Dipaola, et al.
Cancer
|
June 19, 2009
Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group
Robert Dreicer, Hailun Li, Mark Stein, et al.
Plos One
|
December 3, 2015
Combination of α-Tomatine and Curcumin Inhibits Growth and Induces Apoptosis in Human Prostate Cancer Cells
Huarong Huang, Xuan Chen, Dongli Li, et al.
American Journal of Infection Control
|
August 29, 2021
Prevalence of SARS-CoV-2 IgG antibodies in health care workers at a tertiary care academic medical center - An assessment of occupational infection risk
Derek Forster, Nan Lin, Justin Levens, et al.
Urologic Oncology
|
July 26, 2011
Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer
Glenn Liu, Yu-Hui Chen, Jill Kolesar, et al.
Investigational New Drugs
|
November 5, 2010
Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium
Ajjai Alva, Susan Slovin, Stephanie Daignault, et al.
Investigational New Drugs
|
March 23, 2011
A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors
Kyle Holen, Robert DiPaola, Glenn Liu, et al.
Clinical Genitourinary Cancer
|
May 30, 2006
Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design
Kathleen W Beekman, A Dimitrios Colevas, Kathleen Cooney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2018
Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer
Anna C Ferrari, Joshi J Alumkal, Mark N Stein, et al.
Page
of 2